- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04856475
Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer (NeraBrain)
An Open Label Phase II Study to Evaluate Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer
This is an open-label, non-randomised, phase II study to evaluate the efficacy of neratinib in combination with SOC systemic therapy on CNS metastasis both as for secondary prevention (cohort 1), primary treatment (cohort 2) and for the treatment of LM disease (cohort 3) in subjects with HER2 positive metastatic BC.
Subjects with metastatic HER2 positive breast cancer will be eligible for the trial and will be enrolled in one of the following cohorts:
Cohort 1: Eligible subjects include HER2 positive metastatic breast cancer subjects treated with at least one line of systemic anti HER2 therapy and pre-treated with local approaches at least for the previous CNS event and currently progressive but locally treated CNS metastasis. Local therapy includes: stereotactic radiosurgery (SRS) or/and WBRT or/and surgery.
The study will measure the effect of the drug combination on the time to next CNS event(s).
Cohort 2: Eligible subjects include HER2 positive metastatic breast cancer subjects treated with at least one line of systemic anti HER2 therapy or progressing less than 12 months after end of adjuvant therapy with a first diagnosis of brain metastases.
The study will measure the objective CNS response in each subject.
Cohort 3: Eligible subjects include HER2 positive metastatic breast cancer subjects treated with at least one line of systemic anti HER2 therapy with confirmed LM defined as the presence of malignant cells in the cerebrospinal fluid (CSF) or combination of typical symptoms and MRI.
The study will measure the effect of the drug combination on the time to CNS progression including LM progression.
As per investigator's choice, eligible subjects in all cohort will receive neratinib in combination with capecitabine or with T-DM1 or with paclitaxel or with vinorelbine as per investigator's choice. Trastuzumab can be added as per investigator's choice to those regimens except for T-DM1.
At screening and during the study treatment period (every 9 weeks), brain MRI for cohort 1 and cohort 2 or contrast-enhanced neuraxis brain and spine MRI for cohort 3 and tumour assessment by thoracic and abdomino-pelvic CT scan for all cohorts should be performed. For cohort 3 only, CSF cytological assessment should also be performed.
Additionally, at screening and at each cycle during the study treatment period, subjects must fill quality of life questionnaires: EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20).
Study Overview
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years old
- ECOG performance status ≤ 2
- Female
- Diagnosis : histologically or cytologically confirmed HER2-positive tumour status according to the ASCO-CAP guidelines (defined as a 3+ score on immunohistochemistry (IHC) and/or positive by in situ hybridisation (ISH)) with brain metastases, estrogen receptor and progesteron receptor status Cohort 1: with CNS metastases pre-treated with local approaches for the previous CNS events and currently progressive but locally treated CNS metastasis Cohort 2: with a first diagnosis of CNS metastases, asymptomatic or paucisymptomatic not needing immediate local therapy Cohort 3: with confirmed LM defined as the presence of malignant cells in the CSF or combination of typical symptoms and MRI findings
- Specific criteria for cohorts 1 and 2 only: Must have radiologically confirmed metastatic brain lesion by MRI measurable by RANO-BM criteria
- Specific criteria for cohort 3 only: LM defined as the presence of malignant cells in the CSF or combination of typical symptoms and MRI findings for cohort 3
- Subjects should have received at least 1 previous line for the metastatic disease including taxanes based chemotherapy in combination with trastuzumab and pertuzumab (if available) unless contraindicated. Prior tucatinib is not an exclusion criteria.
- Corticosteroids may be used as long as subjects are on a stable or decreasing dose for at least 7 days prior to study enrolment
- Serum pregnancy test (for subjects of childbearing potential) negative within 7 days prior to first neratinib administration
- Women of childbearing potential must agree to use 1 highly effective or 2 effective methods of contraception (as defined at the protocol section 6.8.1) during the course of the study and at least 7 months after the last administration of study treatment.
Adequate bone marrow function as defined below:
- Absolute neutrophil count ≥1500/µL or 1.5x109/L
- Hemoglobin ≥ 9 g/dL
- Platelets ≥100000/µL or 100x109/L
Adequate liver function as defined below:
- Serum total bilirubin ≤ 1.5 x ULN. In case of known Gilbert's syndrome < 3 x ULN is allowed
- AST (SGOT)/ALT (SGPT) ≤ 2.5 x ULN (except in case of liver metastases AST/ALT ≤ 5 x ULN)
Adequate renal function as defined below:
• Creatinine ≤ 1.5 x UNL or creatinine clearance >60 mL/min
- Signed Informed Consent form (ICF) obtained prior to any study related procedure
- LVEF > 55% Inclusion criterion applicable to FRANCE only 1)16) Affiliated to the French Social Security System
Exclusion Criteria:
- CNS disease requiring immediate neurosurgical intervention (e.g. resection, shunt placement, etc.)
- Any unresolved toxicity ≥ CTCAE grade 2 (except alopecia) from previous anti-cancer therapy
- Is ineligible for or has already received all chemotherapy options among the physician's choice
- Any evidence of severe or uncontrolled systemic disease such as clinically significant cardiovascular, pulmonary, hepatic, renal or metabolic disease
- Specific criteria for cohort 2 only: Previous local treatment for CNS metastases
- Specific criteria for cohort 2 only: Oligometastatic disease restricted to the CNS and for which a local treated is considered as the most appropriate treatment by the investigator.
- Known DPD deficiency* tested by measuring the level of uracil in the blood, or by checking for the presence of certain mutations in the gene for DPD according to EMA recommendation in case investigator's choice is capecitabine
- Received an investigational anti-cancer drug within four weeks or five half-lives (whichever is shorter) of study drug administration
- Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs
- Known HIV, Hepatitis B or Hepatitis C infection
- Pregnant and/or lactating women
- Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study
- Contra-indication for contrast-enhanced MRI (either hypersensitivity to Gd chelate or absolute contra-indication for MRI such as non compatible cardiac stimulator) * Testing of subjects for DPD deficiency in case of capecitabine is proposed according to local practices Exclusion criterion applicable to FRANCE only Vulnerable persons according to the article L.1121-6 of the Public Health Code, adults who are the subject of a measure of legal protection or unable to express their consent according to article L.1121-8 of the Public Health Code
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HER2 metastatic breast cancer locally pretreated for previous CNS events and currently progressive
Eligible subjects will receive neratinib in combination with capecitabine or with T-DM1 or with paclitaxel or with vinorelbine as per investigator's choice. Trastuzumab can be added as per investigator's choice to those regimens except for T-DM1. At screening and during the study treatment period (every 9 weeks), brain MRI and tumour assessment by thoracic and abdomino-pelvic CT scan should be performed. Additionally, at screening and at each cycle during the study treatment period, subjects must fill quality of life questionnaires: EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20). |
As per investigator's choice, eligible subjects in all cohort will receive:
|
Experimental: HER2 positive metastatic breast cancer patients with newly diagnosed brain metastases
Eligible subjects will receive neratinib in combination with capecitabine or with T-DM1 or with paclitaxel or with vinorelbine as per investigator's choice. Trastuzumab can be added as per investigator's choice to those regimens except for T-DM1. At screening and during the study treatment period (every 9 weeks), brain MRI and tumour assessment by thoracic and abdomino-pelvic CT scan should be performed. Additionally, at screening and at each cycle during the study treatment period, subjects must fill quality of life questionnaires: EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20). |
As per investigator's choice, eligible subjects in all cohort will receive:
|
Experimental: HER2 positive metastatic breast cancer patients with leptomeningeal carcinomatosis
Eligible subjects will receive neratinib in combination with capecitabine or with T-DM1 or with paclitaxel or with vinorelbine as per investigator's choice. Trastuzumab can be added as per investigator's choice to those regimens except for T-DM1. At screening and during the study treatment period (every 9 weeks), contrast-enhanced neuraxis brain and spine MRI and tumour assessment by thoracic and abdomino-pelvic CT scan should be performed. CSF cytological assessment should also be performed. Additionally, at screening and at each cycle during the study treatment period, subjects must fill quality of life questionnaires: EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20). |
As per investigator's choice, eligible subjects in all cohort will receive:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
For cohort1: Efficacy of neratinib in combination with systemic treatment at investigator's choice in preventing the next CNS event in HER2 breast cancer with known and treated brain metastasis
Time Frame: From date of enrolment until the date of subsequent documented CNS event, assessed up to 6 months
|
The efficacy will be assessed by calculating the ratio of the time to the subsequent CNS event (T2) according to RANO-BM criteria to the time between the current CNS event and previous CNS event (T1) both treated locally (T2/T1). The subsequent CNS event is defined as progression of known and treated brain lesions as well as the development of new brain lesions as assessed on magnetic resonance imaging (MRI) using the RANO-BM criteria. The time to a subsequent CNS event is defined as the time from treatment start of a CNS event to the occurrence of the following one for both T1 and T2 |
From date of enrolment until the date of subsequent documented CNS event, assessed up to 6 months
|
For cohort 2: Efficacy of neratinib in combination with systemic treatment at investigator's choice on previously untreated brain metastasis from HER2 metastatic breast cancer
Time Frame: From date of enrolment until the date of first documented CNS event, assessed up to 6 months
|
The efficacy will be assessed by calculating the proportion of subjects with an objective CNS response, according to RANO-BM criteria in the absence of progressive extra-CNS disease (according to RECIST 1.1).
|
From date of enrolment until the date of first documented CNS event, assessed up to 6 months
|
For cohort 3: Efficacy of neratinib in combination with systemic treatment at investigator's choice on LM disease from HER2 metastatic breast cancer
Time Frame: From date of enrolment until the date of first documented leptomeningeal progression or date of death from any cause, whichever came first, assessed up to 6 months
|
The efficacy will be assessed by measuring CNS progression-free survival defined as the time between treatment start and date of first leptomeningeal progression (defined according to clinical-neurological or imaging criteria) in the absence of progressive extra-CNS disease (according to RECIST 1.1) or date of death (death from any cause) whatever occurs first.
|
From date of enrolment until the date of first documented leptomeningeal progression or date of death from any cause, whichever came first, assessed up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of neratinib in combination with systemic treatment according to investigator's choice on brain metastasis
Time Frame: From date of enrolment until the date of next documented progression or date of death from any cause, whichever came first, assessed up to 6 months
|
Occurrence of new brain metastases according to RECIST 1.1
|
From date of enrolment until the date of next documented progression or date of death from any cause, whichever came first, assessed up to 6 months
|
For cohort 2 only: Evaluation of the time to the first CNS local treatment
Time Frame: From date of enrolment until the date of first documented CNS event, assessed up to 6 months
|
Mesure of the time to the first CNS local treatment
|
From date of enrolment until the date of first documented CNS event, assessed up to 6 months
|
Efficacy of neratinib in delaying the time to whole brain radiotherapy (WBRT) in HER2 breast cancer with known brain metastasis (for subject not previously submitted to WBRT)
Time Frame: From date of enrolment until the date of next documented progression or date of death from any cause, whichever came first, assessed up to 6 months
|
Mesure of the time to whole brain radiotherapy (WBRT)
|
From date of enrolment until the date of next documented progression or date of death from any cause, whichever came first, assessed up to 6 months
|
Safety of neratinib
Time Frame: Assessed up to 6 months
|
Evaluation of the adverse events
|
Assessed up to 6 months
|
Evaluation of the overall survival (OS)
Time Frame: up to 2 years
|
Mesure of the number of overall survival
|
up to 2 years
|
Brain, systemic and bi-comportemental efficacy
Time Frame: Through study completion, up to 2 years
|
Mesure of Clinical Benefit (CB) according to RANO-BM criteria and RECIST 1.1
|
Through study completion, up to 2 years
|
Brain, systemic and bi-comportemental efficacy
Time Frame: Through study completion, up to 2 years
|
Mesure of Objective Response Rate (ORR) - including intracranial ORR according to RANO-BM criteria and RECIST 1.1
|
Through study completion, up to 2 years
|
Brain, systemic and bi-comportemental efficacy
Time Frame: Through study completion, up to 2 years
|
Mesure of Best Response (BR) according to RANO-BM criteria and RECIST 1.1
|
Through study completion, up to 2 years
|
Brain, systemic and bi-comportemental efficacy
Time Frame: Through study completion, up to 2 years
|
Mesure of CNS Progression-Free survival according to RANO-BM criteria and RECIST 1.1
|
Through study completion, up to 2 years
|
Brain, systemic and bi-comportemental efficacy
Time Frame: Through study completion, up to 2 years
|
Mesure of Extra CNS Progression-Free survival.
Assessment of extra-CNS lesions will use the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
|
Through study completion, up to 2 years
|
Brain, systemic and bi-comportemental efficacy
Time Frame: Through study completion, up to 2 years
|
Mesure of overall Progression-Free Survival (PFS) according to RANO-BM criteria and RECIST 1.1
|
Through study completion, up to 2 years
|
Brain, systemic and bi-comportemental efficacy
Time Frame: Through study completion, up to 2 years
|
Mesure of Duration of Response (DoR) according to RANO-BM criteria and RECIST 1.1
|
Through study completion, up to 2 years
|
Brain, systemic and bi-comportemental efficacy
Time Frame: Through study completion, up to 2 years
|
Mesure of Duration of Clinical Benefit (DCB) according to RANO-BM criteria and RECIST 1.1
|
Through study completion, up to 2 years
|
Assessment of the quality of life
Time Frame: Assessed up to 6 months
|
Analysis of Quality of life questionnaire "EORTC QLQ-C30"
|
Assessed up to 6 months
|
Assessment of the quality of life
Time Frame: Assessed up to 6 months
|
Analysis of Quality of life questionnaire "Brain module QLQ-BN20"
|
Assessed up to 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Nuria Kotecki, MD, Jules Bordet Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IJB-NERABRAIN-ODN-007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Neratinib
-
Puma Biotechnology, Inc.Completed
-
UNC Lineberger Comprehensive Cancer CenterNo longer available
-
Pierre Fabre MedicamentNot yet recruiting
-
Puma Biotechnology, Inc.Completed
-
Puma Biotechnology, Inc.Completed
-
Puma Biotechnology, Inc.Completed
-
Pierre Fabre Pharma GmbHiOMEDICO AG; Pierre Fabre Pharma Austria; Pierre Fabre Pharma AGActive, not recruiting
-
Puma Biotechnology, Inc.Completed
-
Puma Biotechnology, Inc.Completed
-
Puma Biotechnology, Inc.Withdrawn